Lexicon Pharma shares plummet after FDA denies appeal against drug rejection
Shares of Lexicon Pharmaceuticals Inc plunged 40% on Monday after the company's appeal to the U.S. health regulator's rejection of its add-on treatment for type 1 diabetes patients was denied.
No comments:
Post a Comment